Iradimed (IRMD) Current Deferred Revenue (2013 - 2026)

Iradimed (IRMD) has 14 years of Current Deferred Revenue data on file, last reported at $7.2 million in Q1 2026.

• Quarterly Current Deferred Revenue rose 23.34% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 23.34% YoY) and the FY2025 annual result came in at $2.9 million, down 45.35% from the prior year.
• Current Deferred Revenue advanced to $7.2 million in Q1 2026 per IRMD's latest filing, from $2.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $7.2 million in Q1 2026 and bottomed at $1.6 million in Q3 2022.
• The 5-year median for Current Deferred Revenue is $2.6 million (2023), against an average of $3.1 million.
• Peak annual rise in Current Deferred Revenue reached 148.03% in 2025, while the deepest fall reached 45.35% in 2025.
• Tracing IRMD's Current Deferred Revenue over 5 years: stood at $3.4 million in 2022, then fell by 23.8% to $2.6 million in 2023, then surged by 104.36% to $5.3 million in 2024, then slumped by 45.35% to $2.9 million in 2025, then surged by 149.18% to $7.2 million in 2026.
• Per Business Quant, the three latest IRMD Current Deferred Revenue figures stand at $7.2 million (Q1 2026), $2.9 million (Q4 2025), and $3.2 million (Q3 2025).

Peer Comparison